OtherInflammation and Immunopharmacology
Valdecoxib: Assessment of COX-2 potency and selectivity
James K. Gierse, Yan Zhang, William F. Hood, Mark C. Walker, Jennifer S. Trigg, Timothy J. Maziasz, Carol M. Koboldt, Jerry L. Muhammad, Ben S. Zweifel, Jaime L. Masferrer, Peter C. Isakson and Karen Seibert
Journal of Pharmacology and Experimental Therapeutics October 19, 2004, DOI: https://doi.org/10.1124/jpet.104.076877
James K. Gierse
Yan Zhang
William F. Hood
Mark C. Walker
Jennifer S. Trigg
Timothy J. Maziasz
Carol M. Koboldt
Jerry L. Muhammad
Ben S. Zweifel
Jaime L. Masferrer
Peter C. Isakson
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
OtherInflammation and Immunopharmacology
Valdecoxib: Assessment of COX-2 potency and selectivity
James K. Gierse, Yan Zhang, William F. Hood, Mark C. Walker, Jennifer S. Trigg, Timothy J. Maziasz, Carol M. Koboldt, Jerry L. Muhammad, Ben S. Zweifel, Jaime L. Masferrer, Peter C. Isakson and Karen Seibert
Journal of Pharmacology and Experimental Therapeutics October 19, 2004, DOI: https://doi.org/10.1124/jpet.104.076877
OtherInflammation and Immunopharmacology
Valdecoxib: Assessment of COX-2 potency and selectivity
James K. Gierse, Yan Zhang, William F. Hood, Mark C. Walker, Jennifer S. Trigg, Timothy J. Maziasz, Carol M. Koboldt, Jerry L. Muhammad, Ben S. Zweifel, Jaime L. Masferrer, Peter C. Isakson and Karen Seibert
Journal of Pharmacology and Experimental Therapeutics October 19, 2004, DOI: https://doi.org/10.1124/jpet.104.076877
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement